Aetion

Real-world data (RWD) is essential for evidence generation, but its use may be limited by privacy regulations, data availability, and systemic biases. In a new whitepaper, now available on the Aetion Evidence Hub, Natalie Schibell, MPH ? (VP, Market Strategy & Communications) and Lucy Mosquera, MSc (Sr. Director, Generate Operations & Data Science) walk us through how #syntheticdata offers a scientifically rigorous approach to overcome these limitations by replicating real-world insights that preserve statistical accuracy and safeguarde patient privacy. Download the whitepaper now to learn how Aetion? Generate is reshaping healthcare research with a validated approach to high-utility, privacy-protected synthetic data: https://hubs.li/Q03cJfSq0

In a recent interview with NY CityBiz, Aetion's co-founder and CEO Jeremy Rassen discusses the increasing role of #RWD in drug development, how Aetion couples AI and scientific rigor to advance evidence generation, and what the future holds for data-driven decision-making in healthcare. Check out the full interview here: https://hubs.li/Q03cB_P50

One day left—reserve your spot now. Low accrual remains a major hurdle in clinical research, limiting the success and efficiency of clinical trials. AI-driven generative models are changing the landscape by simulating patient cohorts to overcome enrollment challenges and rescue poorly recruiting trials. Tomorrow’s live webinar will explore: - Results from groundbreaking new research using oncology trials - The role of synthetic data in reaching recruitment targets - Real-world applications and regulatory considerations Featured speakers: - Lucy Mosquera, Senior Director, Generate Operations & Data Science, Aetion - Dr. Samer El Kababji, Associate Scientist, CHEO RI - Dr. Khaled El Emam, Professor, University of Ottawa Don’t miss this discussion on the future of clinical trial recruitment. Register here: https://hubs.li/Q03clGtp0

Regulators are increasingly leveraging real-world evidence (#RWE) to inform medical device approvals, labeling updates, and long-term safety evaluations. In collaboration with National Evaluation System for health Technology Coordinating Center (NEST), Intuitive, and the FDA, Aetion analyzed long-term outcomes from nearly 25,000 patients to demonstrate that long-term survival rates for robotic-assisted radical prostatectomy are comparable to open surgery, supporting an update to the device labeling. Learn more about how RWE can support #regulatory decisions and promote a deeper understanding of #meddevice performance in real-world settings in a new blog by Natalie Schibell, MPH ?, now available on the Aetion Evidence Hub: https://hubs.li/Q03c6wV00

Global regulations like GDPR, HIPAA, Quebec’s Law 25, and the European Health Data Space (EHDS) are influencing how real-world data (RWD) is accessed, transferred, and used. In our new blog, authors Lucy Mosquera (Sr. Director, Generate Operations and Data Science) and Natalie Schibell, MPH ? (VP, Market Strategy & Communications) demonstrate how proper de-identification can ensure compliance with GDPR, HIPAA, and emerging frameworks like EHDS while also unlocking critical business advantages from data commercialization to AI model training. Learn how Aetion? Generate delivers scientifically validated de-identification now on the Aetion Evidence Hub: https://hubs.li/Q03bLgNK0

Is your clinical trial struggling to recruit? Patient recruitment shortfalls are among the most significant challenges in clinical research, often leading to underpowered studies, increased patient risk, and regulatory delays. Join us on March 19 for a live webinar showcasing groundbreaking new research on how AI-driven generative models can be used to simulate patient cohorts to bridge enrollment challenges and rescue poorly recruiting trials. Featured speakers: - Lucy Mosquera, Senior Director, Generate Operations & Data Science, Aetion - Dr. Samer El Kababji, Associate Scientist, CHEO RI - Dr. Khaled El Emam, Professor, University of Ottawa Register now to gain insights from leading clinical research and data science experts. Register here: https://hubs.li/Q03bvFN20 #ClinicalTrials #RWE #GenerativeModels #AIinHealthcare

#RealWorldEvidence (RWE) was a hot topic at #HIMSS25, appearing in more than 50 sessions. We love to see RWE take center stage because we know it’s a powerful tool we can leverage across the healthcare industry, from optimizing drug development to accelerating regulatory decision-making, and ensuring that the right treatments reach the right patients at the right time. At Aetion we’re aligned with HIMSS 2025’s theme, “creating tomorrow’s health,” through our commitment to improve patient outcomes with data science-driven technology. See how we’re delivering RWE for better healthcare decision-making: https://hubs.li/Q03bjNlb0

At Aetion, we've built our platform to work with any data model while maintaining scientific rigor. Whether you're using OMOP, proprietary structures, or specialized datasets, we’re able to transform your #RWD into trusted evidence that meets regulatory, payer, and commercial standards. Learn how we deliver interoperability without sacrificing analytic integrity in a new blog, now available on the Aetion Evidence Hub: https://hubs.li/Q039Wsqv0

Our Product and Science teams here at Aetion work hand-in-hand to ensure our solutions are not just industry-leading but scientifically rigorous. In our new blog series, Behind the Evidence: Conversations at the Intersection of Product and Science, we spotlight the A-teamers at the heart of this collaboration. For our first Q&A, we sat down with Brenna Kirk, Associate Director, Science, to talk about her journey at Aetion, her move to our Barcelona Tech Hub, and how she helps customers maximize the value of Aetion? Substantiate and Discover. Check out the full Q&A here: https://hubs.li/Q039qKC30

Traditional data sources often miss the complex clinical and biological nuances of inflammatory bowel disease (IBD). Partnering with the Crohn's & Colitis Foundation and IBD Plexus, we’ve developed a Crohn's disease progression score to better understand disease progression, define patient subgroups, and optimize treatment strategies. Read our full blog to discover how Aetion and IBD Plexus are reshaping the future of IBD drug development: https://hubs.li/Q0391Bmy0